Research Cluster
Hair Loss, Follicle Biology & Scalp Health Peptides
Hair follicle cycling is one of the few examples of cyclical organogenesis in adult mammals—a repeating program of growth (anagen), regression (catagen), and rest (telogen) that continues throughout life and depends on a tightly regulated network of signaling pathways. Wnt/β-catenin signaling drives anagen entry and follicle regeneration. IGF-1 and KGF support follicle keratinocyte proliferation. Substance P and neurogenic signaling modulate follicle cycling in both directions. The peptide biology here is real and well-characterized at the molecular level.
The clinical evidence record in this cluster is thinner than the molecular biology. One approved drug. Three active clinical programs. A cosmetic peptide industry that has generated human use data outside the clinical trial framework. The gap between the quality of the preclinical follicle biology and the paucity of rigorous clinical trials is the central fact about this field.
Cluster at a Glance
9 compounds • 1 FDA-approved (different primary indication) • 3 Phase I/II clinical programs • 2 pilot/limited human data • 3 preclinical only
Approved Drug
Clinical Trials
Pilot / Human Data
Preclinical Only
Acetyl Tetrapeptide-3: What the Research Actually Shows
ECM-anchoring peptide combined with biochanin A (a 5-alpha-reductase inhibitor) in the Capixyl formulation. Human data is manufacturer-sponsored and tests the combination, not the peptide alone.
Read the research →
AHK-Cu (Copper Tripeptide-2): What the Research Actually Shows
Synthetic copper-chelating tripeptide (Ala-His-Lys + Cu²⁺). Related to but distinct from GHK-Cu — different sequence, different evidence base, no published human clinical trials. In vitro collagen stimulation and wound healing data. Frequently confused with GHK-Cu; evidence does not transfer between compounds.
Read the research →
Biotinoyl Tripeptide-1: What the Research Actually Shows
Biotin-conjugated GHK peptide targeting follicle anchoring via laminin-5 and collagen IV upregulation. Clinical evidence exists only within the Procapil combination—no standalone human data.
Read the research →
Copper Peptides for Hair: GHK-Cu vs AHK-Cu
GHK-Cu and AHK-Cu—copper-binding tripeptides with distinct mechanisms. GHK-Cu has topical human data from wound healing and skin contexts; hair-specific clinical evidence is limited to cosmetic-use observations.
Read the research →
GHK-Cu: What the Research Says about the Copper Peptide
Copper-binding tripeptide studied for wound healing, collagen synthesis, and skin remodeling. Evidence varies significantly by route of administration.
Read the research →
WADA
IGF-1 and Hair Loss: What the Research Actually Shows
Growth factor mediating many of GH's effects on tissues including hair follicles. WADA-prohibited. Systemic administration carries hypoglycemia risk—follicle-level delivery remains an unsolved problem.
Read the research →
KGF / Palifermin: What the Research Actually Shows
FDA-approved for oral mucositis (Kepivance). FGFR2b-mediated follicle keratinocyte proliferation is well-characterized, but no clinical trials exist for hair loss specifically.
Read the research →
PTD-DBM: What the Research Actually Shows
Cell-penetrating peptide targeting the Wnt/β-catenin pathway—the master switch for follicle regeneration. Published RCTs compare favorably to minoxidil 3%, but trials are small, industry-associated, and unreplicated.
Read the research →
Substance P and Hair Loss: What the Research Actually Shows
Neuropeptide involved in neurogenic inflammation and follicle cycling. NK1 receptor antagonism—not supplementation—is the therapeutic rationale. Human biopsy data supports the catagen-induction pathway.
Read the research →
WADA
Thymosin Beta-4: What the Research Shows
Endogenous 43-amino acid actin-sequestering peptide studied for wound healing, cardiac repair (RGN-352 Phase II), and corneal regeneration (RGN-259). TB-500 is its synthetic fragment — distinct compounds.
Read the research →
Thymulin and Hair Loss: What the Research Actually Shows
Thymic nonapeptide modulating follicle immune privilege via T-cell regulation. No human hair loss trials. The thymic-follicle immune connection is mechanistically plausible but clinically unvalidated.
Read the research →
How These Compounds Relate
The nine compounds in this cluster address follicle biology through five distinct mechanistic layers. PTD-DBM targets the Wnt/CXXC5 signaling brake that prevents anagen entry—the most upstream intervention in the cluster. KGF/palifermin and IGF-1 act on follicle keratinocyte proliferation and survival via receptor-mediated growth factor signaling. Thymosin beta-4 activates quiescent bulge stem cells via metalloproteinase-mediated mobilization. GHK-Cu and acetyl tetrapeptide-3 work at the ECM and structural support level of the follicle niche. Thymulin modulates follicle immune privilege via thymic immune mechanisms. Substance P represents the neurogenic inflammatory pathway that can collapse follicle immune privilege and drive catagen.
The most intellectually coherent interventions in this cluster target specific, well-characterized checkpoints: PTD-DBM’s CXXC5-Dvl blockade is a precise molecular intervention designed from a defined negative feedback mechanism. Substance P’s role in neurogenic alopecia areata is grounded in human biopsy pathology. Thymulin’s immune privilege modulation has a mechanistically plausible thymic–follicle connection. These are more specific targets than the generic “growth factor support” framing of many cosmetic peptide claims.
The evidence gap in this cluster is the most uniform of any on the site: good to excellent preclinical and mechanism biology, thin to absent Phase II/III clinical data. The cosmetic industry has generated human use data for GHK-Cu and acetyl tetrapeptide-3 outside the clinical trial framework, which is documented for what it is. The absence of rigorous controlled trials for most compounds here is not unique to peptides—the androgenetic alopecia drug development landscape is broadly thin outside minoxidil and finasteride, and the follicle biology compounds have not attracted the Phase III investment that other therapeutic areas have.